Analysts Set Zoetis Inc. (NYSE:ZTS) Price Target at $152.91

Zoetis Inc. (NYSE:ZTS) has earned a consensus rating of “Hold” from the thirteen brokerages that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and five have issued a buy rating on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $152.9091.

A number of research firms have issued reports on ZTS. BTIG Research reiterated a “buy” rating and issued a $160.00 target price on shares of Zoetis in a research note on Wednesday, December 3rd. HSBC set a $140.00 price objective on shares of Zoetis in a report on Wednesday, December 10th. The Goldman Sachs Group upgraded shares of Zoetis to a “buy” rating in a research report on Monday, December 15th. KeyCorp initiated coverage on shares of Zoetis in a research note on Thursday, November 20th. They set a “sector weight” rating for the company. Finally, Piper Sandler restated a “neutral” rating and issued a $135.00 price target (down previously from $190.00) on shares of Zoetis in a research note on Thursday, January 22nd.

Zoetis Stock Performance

Shares of NYSE ZTS opened at $128.73 on Wednesday. The company has a quick ratio of 1.94, a current ratio of 3.03 and a debt-to-equity ratio of 2.71. The firm’s 50-day moving average price is $125.41 and its two-hundred day moving average price is $134.80. Zoetis has a 52-week low of $115.25 and a 52-week high of $177.00. The stock has a market capitalization of $54.34 billion, a P/E ratio of 21.38, a P/E/G ratio of 1.94 and a beta of 0.96.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. The business had revenue of $2.39 billion for the quarter, compared to analysts’ expectations of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The business’s quarterly revenue was up 3.0% on a year-over-year basis. During the same period in the prior year, the firm earned $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, sell-side analysts forecast that Zoetis will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be given a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 1.6%. The ex-dividend date is Monday, April 20th. Zoetis’s dividend payout ratio (DPR) is currently 35.22%.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Halbert Hargrove Global Advisors LLC lifted its holdings in Zoetis by 496.6% in the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after acquiring an additional 144 shares during the last quarter. Global Wealth Strategies & Associates bought a new stake in shares of Zoetis in the 4th quarter worth approximately $25,000. Prosperity Bancshares Inc bought a new stake in shares of Zoetis in the 4th quarter worth approximately $25,000. NewSquare Capital LLC lifted its stake in Zoetis by 69.1% during the second quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock valued at $32,000 after purchasing an additional 85 shares during the last quarter. Finally, KERR FINANCIAL PLANNING Corp bought a new stake in Zoetis during the third quarter worth approximately $31,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.